Many presentations with a first seizure pose significant challenges for clinicians. As demonstrated in this special issue by several experts, the occurrence of what is believed to be a firstever seizure raises multiple questions, and the formulation of meaningful guidance for individual patients requires clinicians to consider a range of different perspectives. The evolving concept of a seizure as the "loudest noise" in an altered functional and structural brain environment [1] is intriguing and will require more sophisticated examination and curious exploration. However, this concept impacts on several areas in the field of first seizure research and management. We want to emphasize three specific themes.
Terms and definitions have to be revised continuously to reflect our increasing understanding of ictogenesis and epileptogenesis
The recent revision of "A practical definition of epilepsy" by an ILAE Task Force after almost 10 years [2] nicely reflects our increasing, but still limited knowledge of epileptogenesis. There is a fine line between what appears to be a first isolated and single seizure and the diagnosis of epilepsy as on-going condition characterized by an increased risk of seizure recurrence. The authors emphasize that the traditional definition of epilepsy (the occurrence of two unprovoked seizures separated by more than 24 h) has served us well in the past, but "is inadequate in some clinical circumstances". As previously outlined in their first paper [3] , the ILAE Task Force now considers patients with a single first unprovoked seizure to have epilepsy if their medical history suggests a remote etiological factor such as prior stroke, infection or trauma. Based on very few prospective studies and a review [4, 5] , the risk of seizure recurrence in these patients who have only experienced one definite seizure is estimated to be >60% and therefore comparable to the seizure recurrence risk of patients who have had two unprovoked seizures and no previous medical history suggesting a remote etiology, justifying the diagnosis of epilepsy as an enduring condition with a lowered seizure threshold.
We entirely agree with the task force's recent concerns [2] that the current classification and categorization into provoked and unprovoked seizures has "imprecise borders"
In line with a previous publication [1] , the updated definition raises the question if "unprovoked" and "provoked" represent distinct categories or whether there is actually a continuum ranging from more subtle, "hidden", to more obvious provoking factors. If the term "unprovoked" is used to imply an absence of a temporary or reversible factor lowering the threshold [2] , it is important to consider the issue of awareness or consciousness. We cannot expect all patients or seizure witnesses to have been aware of all possible provoking factors or to recall such factors. The absence of reports of possible provoking factors does not necessarily mean that a seizure was not provoked.
Issues of awareness or consciousness are also relevant in other ways. The recognition that a seizure has occurred is dependent on witnesses or on an individual's ability to recognize that it has "happened". The first seizure is a theoretical construct, as it is often possible that an unnoticed seizure may have occurred at an earlier point in time, eg. during sleep. On the other hand, first ever single seizures which seem to be "acutely provoked" should not automatically be misinterpreted as benign, isolated events, as they frequently mark the first presentation of primary generalized epilepsy, an enduring condition. Lack of sleep or alcohol access are among the most frequently reported factors.
A mishmash of terms such as "provoking", "contributing", "facilitating" or "triggering" factors is currently in use, but there is no universal agreement on the precise meaning or delineation of any of these terms. Biological systems seem to work in more complex ways with many different interactions between mechanistic components. Today's classification dilemma is therefore the reflection of the continuing deficiency of our deeper understanding of how subtle factors actually play "in concert" and what the role of each instrument is. The scenario is further complicated by the fact that the seizure threshold is likely to be individually determined, allowing for considerable inter-individual differences in terms of the impact of various "provoking" factors. Increasingly sensitive diagnostic tools and the constant improvement of both, diagnostic algorithms in clinical settings and animal models of first seizures, will hopefully provide us with a more sophisticated understanding of these issues in the future.
The role of the time domain, more specifically, the time which has elapsed between a first and a second seizure is another unresolved issue. The ILAE Task Force [2] provides an illustrative example where even in presence of 2 "unprovoked 'seizures separated by 80 years the current definition of epilepsy would apply although this is a clinical scenario which differs markedly from what we would usually perceive as epilepsy. We understand that there is currently no rationale for a specific time interval between seizures that would "reset the clock" so a second seizure Contents lists available at ScienceDirect Seizure j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / y s e i z would be considered as another isolated event rather than an occurrence defining the development of epilepsy [2] . However, we agree with the Task Force that 'such a rational might emerge from future research'.
Recently we suggested the implementation of a time domain or time axis in the definitions of new-onset epilepsy (NOE) and newly diagnosed epilepsy (NDE), rather than using the absolute number of seizures for the distinction of these terms, as absolute numbers are hard to assess and often speculative [6] . We proposed that the term NOE should be used for any patient whose first seizure is followed by one or more seizures within 12 months, while patients presenting with their first seizure and found to have had preceding seizures for more than 12 months (often many years) would be diagnosed with NDE. NOE would therefore become a subcategory of NDE. This concept hypothetically assumes that the terms FS (first seizure), NOE and NDE reflect different stages and extensions of epileptic networks.
Clinical assessment of risk for seizure recurrence and individually tailored management and treatment plans
One of the most important issues for the neurologist tasked with advising patients with a PFS is to provide them with a precise individual assessment of the seizure recurrence (SR) risk, so that well-founded decisions about drug treatment, overall management and counseling can be made.
We have learned from group data and a hallmark meta-analysis [7, 8] that the SR risk after a first seizure is usually in the range of 30%-70% within 2 years (mean average 40-50%). Recurrence rates are highest in the first few months; etiology and pathological EEG seem to be the strongest predictors for SR.
But how can we apply this "knowledge" to an individual patient? A prognostic model was developed based on individual patient data from the MESS study (UK Multicentre study of early epilepsy and single seizures, early versus late treatment) to identify patients at low, medium, or high risk of seizure recurrence [9] . This intriguing approach scored the SR risk of each patient based on the total number of seizures of all types at presentation, presence of a neurological disorder, and an abnormal electroencephalogram (EEG). This is a helpful framework and provides a basis for discussion with patients. However, the data pool and our understanding of the factors codetermining SR are still too limited. There is currently no formula including additional SR risk factors, and there is no data on how such risks combine [2] . Clinical experience has confronted us with a wide range of clinical scenarios and unexpected outcomes.
The many unanswered questions demonstrate that there is an urgent need for us to detect new biomarkers providing objective measures of a normal or pathologic biologic process in patients presenting with seizures [10] ; we need more individual predictors allowing us to get better at precisely identifying those who have an inherent propensitiy to generate seizures (ictogenesis) and those who will go on to develop epilepsy (epileptogenesis). Ideally, these discoveries will also lead to new treatment strategies and the development of innovative compounds interfering with the processes underpinning epileptogenesis.
In this context, the neurobehavioral assessment of patients presenting with a first seizure or in the early stages of epilepsy is showing promise [11, 12] , these issues, [13] . There is increasing evidence that brain function is already compromised at the time of first seizure occurrence [14] , with evidence of cognitive disturbances and neuropsychiatric issues which may be very subtle or more severe. Unfortunately, there is only a limited number of welldesigned longitudinal studies so far. Evidence is particularly lacking in adult patients [13, 11] . However, the findings that are available support the interpretation of a PFS as the "tip of the iceberg" [1] and the call for a search for new "clinical" biomarkers. The early detection of network disturbances in first seizure patients reflected by cognitive impairment and psychiatric comorbidities may become a clinical method suitable for routine use and capable of predicting long-term prognosis and even pharmacoresistance. Newly-treated patients with epilepsy were found to be less likely to respond to antiepileptic drugs (AEDs), if they showed higher levels of neuropsychiatric dysfunction in a validated neuropsychiatric test [15] . There is an urgent need for further prospective studies (especially in adolescents and adults), involving neuropsychiatric test batteries at the time of the first seizure presentation.
Finally, we suggest that diagnostic algorithms for first seizure assessment require further development and improvement. In agreement with several older studies, recent research shows that the diagnostic yield from EEG examination is higher in early recordings, optimally performed right after the seizure and while still in the emergency room [16] .
With the constant evolution of new MRI techniques, we expect a better understanding of the relevance of structural lesions for epileptogenesis. The rapidly increasing sensitivity of MRI techniques will provide us with a better opportunity to understand the relevance of subtle texture changes such as focal cortical dysplasia (FCD) with regards to ictogenesis and epileptogenesis. We anticipate a steep learning curve. Our own limited experience of lesions suspicious of FCD in MRI in patients with PFS in a prospective cohort suggests that the majority of these patients remain seizure-free even without treatment in shortterm follow-up [17] [abstract]). This is in contrast to crosssectional studies and clinical experience indicating that FCD are the most frequent MRI lesions found in patients with AED refractory epilepsy. Follow-up in our and other cohorts may still be too short. At present we can only speculate whether, perhaps co-determined by other factors such as aging or additional "hits" to the brain, the same patients become pharmacoresistant as time goes by or that FCDs are associated with a wide range of different levels of intrinsic epileptogenicity. Only systematic longitudinal follow-up over several decades will tell us the "full story" and allow us better to understand these interesting structural abnormalities.
3. Improvement of health care portals in epilepsy programs and need for further systematic prospective studies Finally, we would like to stress the need further to improve rapid and efficient access to comprehensive epilepsy programs embedding innovative prospective study designs.
The optimal management of the first seizure presentation depends on a thorough understanding of the subtleties of the biological processes involved in the early stages of epilepsy. In order to arrive at an early and accurate diagnosis of functional and structural disturbances, the application of the newest diagnostic definitions (with their implications) and an individualized plan for targeted interventions, "specialized diagnostic and interpretative skills" are needed [2] .
The increasing implementation of (often research-driven) First Seizure Clinics (FSC) in comprehensive epilepsy programs around the globe is a logical consequence of this need. Our experience suggests that FSCs allow clinicians and researchers (a) to analyze and optimize referral patterns, (b) to provide high-quality counseling on the basis of advanced additional test procedures, (c) to intervene early at each step of the evolution of the disorder, (d) to identify potential surgical candidates at a much earlier stage, and (e) to achieve better clinical and social outcomes. We believe that universal access to FSC is urgently needed to provide patients with a perfect health care portal, providing efficient access to epilepsy programs and optimally "channeling patient flows" through the complexity of the whole health system.
There is a strong need to perform rigorous prospective and multicenter studies in patients with first seizures and new-onset epilepsy. Well-organised and connected FSC are the ideal basis for this endeavor. Careful longitudinal studies in epilepsy right from the earliest manifestations of the disorder will provide a critical perspective on disease evolution and mechanisms involved determining prognosis and treatment response. Results from a mono-centric cohort attending a research-driven FSC have taught us several important lessons about AED treatment failures and the bigger picture of pharmacoresistance [18] . These data have had immediate impact on our clinical counseling as they have informed us about phenomena which often remain "hidden" in day-to-day practice. Recently, a framework for a research-driven neuroimaging protocol for first seizure patients was introduced [19] , raising the potential of enabling clinicians and researchers to observe subtle structural or functional changes over time.
The early systematic application of screening instruments for subtle disturbances of cognition and psychiatric problems and the collection of blood samples for genetic testing (eg. multidrug resistance genes) are only some examples of the ways in which a clinical portal such as a FSC can easily combine the provision of a high-quality, important health service with a mechanism to answer urgent research questions.
A recent, very promising approach that may address some of the questions we have about the presentation with first seizures is the Human Epilepsy Project (HEP) [20] . The HEP study is a sophisticated, multi-center, five-year, prospective, observational study whose primary goal is to identify clinical characteristics and biomarkers predictive of disease outcome, progression, and treatment response in participants with newly treated focal epilepsy. Unfortunately, we are not aware of an equivalent study in primary generalized epilepsies, although there are, unfortunately, only very few prospective long-term studies providing answers to essential questions such as long-term remission, risk of seizure recurrence, and impact on life-style issues on seizure threshold in these epileptic disorders [21, 22] .
We as a community of neurologists and scientists have to be humble and patient as we try to tackle the uncertainty around so many facets of what we actually believe epilepsy to be. With respect to our patients and our passion to care for them in the best possible way, we would like to quote Rainer Maria Rilke from his book "Letters to a young poet" [23] :
"I want to beg you, as much as I can, dear sir, to be patient toward all that is unsolved in your heart and to try to love the questions themselves like locked rooms and like books that are written in a very foreign tongue. Do not now seek the answers, which cannot be given you because you would not be able to live them. And the point is, to live everything. Live the questions now. Perhaps you will then gradually, without noticing it, live along some distant day into the answer."
